5 High Growth International Stocks to Buy

4. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 48   

argenx SE (NASDAQ:ARGX) is a biotechnology company that focuses on developing various therapies for the treatment of autoimmune diseases. On December 21, investment advisory Truist maintained an Outperform rating on Argenx SE (NASDAQ:ARGX) stock and lowered the price target to $370 from $550. 

At the end of the third quarter of 2023, 48 hedge funds in the database of Insider Monkey held stakes worth $2.2 billion in argenx SE (NASDAQ:ARGX), compared to 47 in the preceding quarter worth $1.9 billion. 

In its Q3 2023 investor letter, TimesSquare Capital Management, an asset management firm, highlighted a few stocks and argenx SE (NASDAQ:ARGX) was one of them. Here is what the fund said:

“Our preference within Health Care is for novel therapies to address unmet medical needs, specialized providers, and innovators. argenx SE (NASDAQ:ARGX) is a global immunology company focused on autoimmune diseases. Their share price advanced 28% after outpacing estimates and aided by sales of Vyvgart for treating myasthenia gravis. Management also gave an encouraging update on clinical readouts and their expanding pipeline.”